AstraZeneca
-
First-of-its-kind AstraZeneca Drug Cuts Risk of Severe COVID-19 by 50%
AstraZeneca company announced on Monday the results of its Phase III COVID-19 treatment trial which showed that their antibody drug is the first of its kind to both prevent and treat COVID-19, and cut the risk of severe COVID-19 by at least 50 percent.
Latest Research Articles